Publication Topic

Jensen I, Halbert R, Giuseppe R, Naoshy S, Iqbal SU, Zhimin X, McSweeney P. 2015. A hospital budget impact model to evaluate plerixafor in stem cell mobilization: Impact of primary research and direct stakeholder engagement. Eur J Hosp Pharm 22(3):142–149; doi: 10.1136/ejhpharm-2014-000543.

Meddings J, Reichert H, Smith S, Iwashyna T, Langa K, Hofer T, McGuirk H, McMahon LF Jr. Functional status, social support and wealth impact readmissions for pneumonia and heart failure beyond standard Medicare risk-adjustors. Academy Health Annual Research Meeting, June 14-15, 2015, Minneapolis, MN.

Doucette A, Jiang X, Fryzek J, Coalson J, McLaurin K, Ambrose CS. Comparison of trends in bronchiolitis and respiratory syncytial virus infant hospitalizations rates in 3 US nationally representative databases. Presented at the Pediatric Academic Societies Annual Meeting, San Diego, CA, April 2015.

Babik I, Libassi L, Movva N, Lobo MA. Rehabilitation intervention changing the dynamics of movement in children with arthrogryposis. Poster presentation at the Society for Research in Child Development Biennial Conference, Philadelphia, PA, March 2015.

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10, ISPOR 17th Annual European Congress 2014.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18^th Annual International Meeting, New Montreal Quebec, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16^th Annual European Congress, Amsterdam, Netherlands, 2014.

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.